{"id":"patanol","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headaches","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Burning or stinging","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Cold syndrome","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Dry eye","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Foreign body sensation","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hyperemia","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hypersensitivity","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Keratitis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Lid edema","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Rhinitis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Sinusitis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Taste perversion","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Epistaxis","Nasal Lesions","Nasal Septal Ulcers","Perforation of nasal septum"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL1189432","moleculeType":"Small molecule","molecularWeight":"337.42"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Patanol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:17:57.486063+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:18:03.280182+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Patanol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:18:03.483063+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1189432/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:18:04.174563+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"ae8b4a9d-4308-4a3c-8ec9-1e8d9060db68","title":"PATANOL (OLOPATADINE HYDROCHLORIDE) SOLUTION/ DROPS [PHYSICIANS TOTAL CARE, INC.]"},"ecosystem":[],"mechanism":{"target":"Histamine H1 receptor, Histamine H1 receptor"},"_scrapedAt":"2026-03-28T03:13:40.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:18:05.775202+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Seasonal allergic rhinitis","diseaseId":"seasonal-allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06126952","phase":"PHASE2","title":"Azelastine Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2023-10-30","conditions":"Seasonal Allergic Rhinitis","enrollment":84},{"nctId":"NCT00836485","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Senju USA, Inc.","startDate":"2009-02","conditions":"Allergic Conjunctivitis","enrollment":122},{"nctId":"NCT04776096","phase":"PHASE4","title":"Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment","status":"COMPLETED","sponsor":"Laboratorios Poen","startDate":"2021-03-10","conditions":"Allergic Conjunctivitis","enrollment":97},{"nctId":"NCT03186755","phase":"PHASE4","title":"Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis","status":"UNKNOWN","sponsor":"Michael Marchand, MD","startDate":"2017-06-11","conditions":"Conjunctivitis, Allergic, Conjunctivitis, Vernal","enrollment":42},{"nctId":"NCT03320434","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis","status":"COMPLETED","sponsor":"ORA, Inc.","startDate":"2017-10-13","conditions":"Allergic Conjunctivitis","enrollment":120},{"nctId":"NCT05314621","phase":"PHASE4","title":"A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Andover Research Eye Institute","startDate":"2021-12-31","conditions":"Allergic Conjunctivitis","enrollment":61},{"nctId":"NCT05265910","phase":"PHASE4","title":"A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Andover Research Eye Institute","startDate":"2021-12-14","conditions":"Allergic Conjunctivitis","enrollment":58},{"nctId":"NCT05353101","phase":"PHASE1","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2020-07-01","conditions":"Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops","enrollment":48},{"nctId":"NCT04708821","phase":"PHASE4","title":"DEXTENZA Therapy for Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Clinical Research Center of Florida","startDate":"2021-04-30","conditions":"Bilateral Conjunctivitis (Disorder)","enrollment":31},{"nctId":"NCT05129306","phase":"","title":"Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes","status":"WITHDRAWN","sponsor":"Community and Patient Preference Research Pty Ltd","startDate":"2021-11-17","conditions":"Allergic Rhinitis","enrollment":""},{"nctId":"NCT02318303","phase":"PHASE2","title":"To Study GSP 301 in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-12","conditions":"Seasonal Allergic Rhinitis","enrollment":1111},{"nctId":"NCT02709538","phase":"PHASE3","title":"Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-04","conditions":"Perennial Allergic Rhinitis","enrollment":601},{"nctId":"NCT03463031","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2018-03-16","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":446},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT02161146","phase":"PHASE3","title":"AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-04","conditions":"Conjunctivitis, Allergic","enrollment":240},{"nctId":"NCT01657240","phase":"PHASE3","title":"Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis","status":"WITHDRAWN","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2014-11","conditions":"Allergic Conjunctivitis","enrollment":""},{"nctId":"NCT02631551","phase":"PHASE3","title":"Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-03","conditions":"Seasonal Allergic Rhinitis","enrollment":1180},{"nctId":"NCT00609128","phase":"NA","title":"Effect of Olopatadine on Allergic Tear Mediators","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2000-09","conditions":"Allergic Conjunctivitis","enrollment":21},{"nctId":"NCT03444506","phase":"PHASE2","title":"Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-01-27","conditions":"Seasonal Allergic Rhinitis","enrollment":180},{"nctId":"NCT02870205","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-08","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":1176},{"nctId":"NCT00789555","phase":"PHASE4","title":"Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-11","conditions":"Perennial Allergic Rhinitis","enrollment":1260},{"nctId":"NCT02322216","phase":"PHASE3","title":"Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-12","conditions":"Allergic Conjunctivitis","enrollment":383},{"nctId":"NCT00578331","phase":"PHASE3","title":"Safety Study of Olopatadine Nasal Spray","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-12","conditions":"Perennial Allergic Rhinitis","enrollment":890},{"nctId":"NCT01700192","phase":"PHASE3","title":"Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2013-01","conditions":"Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal","enrollment":1482},{"nctId":"NCT01495338","phase":"PHASE1","title":"A Comparison of the Safety and Comfort of AC-170","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-12","conditions":"Normal Ocular Health","enrollment":60},{"nctId":"NCT00331500","phase":"PHASE3","title":"Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04-18","conditions":"Allergic Conjunctivitis","enrollment":287},{"nctId":"NCT00775658","phase":"NA","title":"Olopatadine Eye Drops and Allergy Skin Testing","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2008-01","conditions":"Allergic Rhinitis, Allergic Conjunctivitis","enrollment":24},{"nctId":"NCT00562159","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":439},{"nctId":"NCT00550550","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":345},{"nctId":"NCT01294969","phase":"PHASE4","title":"Patient Perception Study for AL-4943A","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Allergic Conjunctivitis","enrollment":47},{"nctId":"NCT00389025","phase":"PHASE4","title":"Mast-Cell Stabilizing Effects of Olopatadine","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-10","conditions":"Allergic Conjunctivitis","enrollment":24},{"nctId":"NCT02251613","phase":"PHASE4","title":"Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Allergic Conjunctivitis","enrollment":50},{"nctId":"NCT00534794","phase":"PHASE4","title":"Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":"Allergic Conjunctivitis","enrollment":79},{"nctId":"NCT01109485","phase":"PHASE4","title":"Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-03","conditions":"Allergic Conjunctivitis","enrollment":42},{"nctId":"NCT01326858","phase":"PHASE1","title":"Safety and Comfort of AL-4943A Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":50},{"nctId":"NCT01363700","phase":"PHASE3","title":"Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"","conditions":"Allergic Conjunctivitis","enrollment":87},{"nctId":"NCT01697969","phase":"PHASE4","title":"Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Allergic Conjunctivitis","enrollment":17},{"nctId":"NCT01743027","phase":"PHASE3","title":"Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-01","conditions":"Allergic Conjunctivitis","enrollment":902},{"nctId":"NCT01037179","phase":"PHASE3","title":"An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-02","conditions":"Allergic Conjunctivitis","enrollment":110},{"nctId":"NCT00987272","phase":"PHASE3","title":"Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-10","conditions":"Allergic Conjunctivitis","enrollment":267},{"nctId":"NCT01698814","phase":"PHASE3","title":"A Six-Week Safety Study of an Investigational Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-10","conditions":"Allergic Conjunctivitis","enrollment":518},{"nctId":"NCT01119287","phase":"PHASE4","title":"Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-03","conditions":"Allergic Conjunctivitis","enrollment":180},{"nctId":"NCT01732757","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11","conditions":"Conjunctivitis, Allergic","enrollment":157},{"nctId":"NCT01450176","phase":"NA","title":"Comparing Patient Satisfaction With Pataday or Bepreve","status":"COMPLETED","sponsor":"McCabe Vision Center","startDate":"2011-09","conditions":"Eye Allergies","enrollment":30},{"nctId":"NCT01287338","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.","status":"TERMINATED","sponsor":"Mati Therapeutics Inc.","startDate":"2010-10","conditions":"Seasonal Allergic Conjunctivitis to Ragweed","enrollment":143},{"nctId":"NCT01007253","phase":"PHASE4","title":"Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-11","conditions":"Seasonal Allergic Rhinitis","enrollment":21},{"nctId":"NCT01479374","phase":"PHASE3","title":"Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-01","conditions":"Allergic Conjunctivitis","enrollment":397},{"nctId":"NCT01470118","phase":"PHASE4","title":"A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Conjunctivitis, Allergic","enrollment":127},{"nctId":"NCT01282138","phase":"PHASE4","title":"Assessment of Alcon's Ocular Image Quantification System","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-12","conditions":"Allergic Conjunctivitis","enrollment":13},{"nctId":"NCT01272089","phase":"PHASE4","title":"A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Allergic Conjunctivitis","enrollment":300},{"nctId":"NCT00818805","phase":"PHASE4","title":"Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-07","conditions":"Allergic Conjunctivitis","enrollment":50},{"nctId":"NCT01344083","phase":"PHASE2","title":"Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2011-04","conditions":"Seasonal Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT01159769","phase":"PHASE4","title":"Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-06","conditions":"Allergic Conjunctivitis","enrollment":215},{"nctId":"NCT01435460","phase":"PHASE3","title":"Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-08","conditions":"Seasonal Allergic Conjunctivitis","enrollment":300},{"nctId":"NCT01076439","phase":"PHASE4","title":"An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo","status":"WITHDRAWN","sponsor":"ORA, Inc.","startDate":"","conditions":"Allergic Rhinitis","enrollment":""},{"nctId":"NCT01258309","phase":"PHASE3","title":"Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-12","conditions":"Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic","enrollment":129},{"nctId":"NCT00979615","phase":"PHASE4","title":"Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-09","conditions":"Vasomotor Rhinitis","enrollment":129},{"nctId":"NCT00489398","phase":"PHASE4","title":"Comparison of CL Wear Between Two Allergy Drops","status":"WITHDRAWN","sponsor":"Hom, Milton M., OD, FAAO","startDate":"2007-07","conditions":"Allergic Conjunctivitis","enrollment":25},{"nctId":"NCT00845195","phase":"PHASE4","title":"Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-03","conditions":"Seasonal Allergic Rhinitis","enrollment":150},{"nctId":"NCT00691665","phase":"PHASE4","title":"Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Seasonal Allergic Rhinitis","enrollment":130},{"nctId":"NCT00794144","phase":"PHASE2","title":"Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Allergic Rhinitis","enrollment":132},{"nctId":"NCT00578929","phase":"PHASE3","title":"Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-09","conditions":"Seasonal Allergic Rhinitis","enrollment":2388},{"nctId":"NCT00772304","phase":"PHASE4","title":"Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Allergic Rhinitis","enrollment":102},{"nctId":"NCT00655109","phase":"PHASE4","title":"A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Greiner, Jack V., OD DO PhD","startDate":"2008-02","conditions":"Conjunctivitis, Allergic","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1189432"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":29,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Patanol","genericName":"Patanol","companyName":"ORA, Inc.","companyId":"ora-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:18:05.775202+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}